08/23/21 9:33 AMNasdaq : NRXP covid-19Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not NecessaryNRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, biopharmaceutical company noted today reports 1 in the Israeli media that participants in the BriLife vaccine trial who received the highest dose vaccine were notified by local health authoritiesRHEA-AIneutral
08/19/21 9:18 AMNasdaq : NRXP NRx Pharmaceuticals Announces $30 Million Private PlacementNRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 2,727,273 shares of common stock in a private placement. The Company will alsoRHEA-AIneutral
08/18/21 11:53 AMNasdaq : NRXP covid-19NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI ™ (aviptadil) which is being tested in the ACTIV-3 Critical Care Phase 3 study sponsored by the National Institutes of Health.RHEA-AIneutral
08/16/21 9:32 PMNasdaq : NRXP NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial UpdateNRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM EasternRHEA-AIneutral
08/11/21 4:20 PMNasdaq : NRXP conferencesNRx Pharmaceuticals to Report Second Quarter 2021 Results August 16, 2021NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company, today announced that management will report second quarter 2021 financial results after theRHEA-AIneutral
08/10/21 6:48 AMNasdaq : NRXP NRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced that the NRx Team, together with Prof Jonathan Javitt, Founder, Chairman and CEO of NRx, will ring the Nasdaq Closing Bell on Tuesday, August 10,RHEA-AIpositive
08/09/21 1:13 PMNasdaq : NRXP clinical trialcovid-19NRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife™ Vaccine for Covid-19 in Nation of GeorgiaNRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced it is initiating a phase 2b dose-confirmatory trial of the BriLife™ vaccine against COVID-19 in the Nation of Georgia. The vaccine is developed byRHEA-AIneutral
08/04/21 6:48 AMNasdaq : MNKD, NRXP MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® PlatformMannKind Corporation (Nasdaq: MNKD) has partnered with NRx Pharmaceuticals (Nasdaq: NRXP) (NRx) to evaluate the feasibility of formulating a dry powder formulation of ZYESAMI ™ (aviptadil), a synthetic form of human Vasoactive IntestinalRHEA-AIneutral
08/04/21 6:48 AMNasdaq : MNKD, NRXP NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory ConditionsNRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with MannKind Corporation to develop a dry powder formulation of ZYESAMI ™ (aviptadil), a synthetic form of human Vasoactive Intestinal Peptide (VIP), produced by the bodyRHEA-AIpositive
07/27/21 11:34 AMNasdaq : NRXP NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of GeorgiaNRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage, global biopharmaceutical company, today announced that the Nation of Georgia's Prime Minister and Minister of Health have issued an Emergency Use Authorization for intravenous ZYESAMI™ (aviptadil)RHEA-AIneutral